tokbokki/tatqa_dataset_filter huggingface dataset:
text: 1998 Employee Qualified Stock Purchase Plan (“ESPP”)
text: Under Autodesk’s ESPP, which was approved by stockholders in 1998, eligible employees may purchase shares of Autodesk’s common stock at their discretion using up to 15% of their eligible compensation, subject to certain limitations, at 85% of the lower of Autodesk's closing price (fair market value) on the offering date or the exercise date. The offering period for ESPP awards consists of four, six-month exercise periods within a 24-month offering period.
text: At January 31, 2019, a total of 8.1 million shares were available for future issuance. Under the ESPP, the Company issues shares on the first trading day following March 31 and September 30 of each fiscal year. The ESPP does not have an expiration date.
text: A summary of the ESPP activity for the fiscal years ended January 31, 2019, 2018 and 2017 is as follows:
text: Autodesk recorded $27.2 million, $25.7 million, and $25.9 million of compensation expense associated with the ESPP in fiscal 2019, 2018, and 2017, respectively.

Table:
Fiscal year ended January 31,
2019
2018
2017
Issued shares
1.0
2.0
2.3
Average price of issued shares
$90.25
$39.03
$36.99
Weighted average grant date fair value of awards granted under the ESPP
$42.75
$32.41
$19.20

Questions:
question: What was the average price of issued shares in the fiscal year ended 2018?
answer: $39.03
question: What is the change in the weighted average grant date fair value of awards granted under the ESPP from 2017 to 2018?
answer: 13.21
derivation: 32.41-19.2
text: Simultaneous with the Merger and the Private Offering, New Warrants to purchase 3,403,367 shares of Series B Preferred Stock at an average exercise price of
approximately $1.05 per share were issued to holders of Prior Protagenic warrants; additionally, the holder of $665,000 of our debt and $35,000 of accrued interest exchanged such debt for five-year warrants to purchase 295,945 shares of Series B Preferred Stock at $1.25 per share. Placement Agent Warrants to purchase 127,346 shares of Series B Preferred Stock at an exercise price of $1.25 per share were issued in connection with the Private offering. These warrants to purchase 423,291 shares of Series B Preferred Stock have been recorded as derivative liabilities. All of these warrants automatically converted into warrants to purchase our common stock upon the effectiveness of our reverse stock split in July 2016. See Note 5.
text: A summary of warrant issuances are as follows:
text: As of December 31, 2019, the Company had 3,826,658 shares issuable under warrants outstanding at a weighted average exercise price of $1.05 and an intrinsic value
of $1,375,990.
text: As of December 31, 2018 the Company had 3,826,658 shares issuable under warrants outstanding at a weighted average exercise price of $1.05 and an intrinsic value of
$3,633,335.

Table:
Warrants
Number
Weighted Average Exercise Price
Weighted Average Remaining Life
Outstanding December 31, 2017
3,826,658
$1.05
4.69
Granted
-
-
-
Outstanding December 31, 2018
3,826,658
$1.05
3.69
Granted
-
-
-
Outstanding December 31, 2019
3,826,658
$1.05
2.69

Questions:
question: What is the weighted average remaining life of the outstanding warrants as at December 31, 2017?
answer: 4.69
question: What is the weighted average remaining life of the outstanding warrants as at December 31, 2018?
answer: 3.69
question: What is the weighted average remaining life of the outstanding warrants as at December 31, 2019?
answer: 2.69
text: 8 Auditor’s remuneration
text: 1 Relates to the interim report review of the Group, and interim reviews of certain subsidiary undertakings.
text: 2 2019 other non-audit assurance services relate primarily to reporting accountants’ work associated with the potential equity raise not completed.
text: The reporting accountants’ work surrounding the potential equity raise not completed includes a working capital report that requires the accountant to have detailed knowledge of the Group. If a firm other than the audit firm were to undertake this work, they would require a significant amount of additional time to become familiar with the Group. Deloitte was therefore chosen to undertake this work as it was considered to be sensible and more efficient both in terms of time and costs.
text: 2018 other non-audit assurance services included £40,000 related to reporting accountants’ work associated with a year end significant change report and £190,000 related to reporting accountants’ work in connection with the Group’s Q3 profit estimate which was required at the time due to Takeover Code rules.
text: The work surrounding a significant change report and a profit estimate requires the accountant to have detailed knowledge of the Group. If a firm other than the audit firm were to undertake this work, they would require a significant amount of additional time to become familiar with the Group. PwC was therefore chosen to undertake this work as it was considered to be sensible and more efficient both in terms of time and costs.
text: As for all 2019 and 2018 non-audit work, consideration was given as to whether Deloitte’s (2019) and PwC’s (2018) independence could be affected by undertaking this work. It was concluded by the Audit Committee that this would not be the case.
text: Fees payable by the Group’s joint ventures in respect of 2019 were £156,000 (Group’s share), all of which relates to audit and audit-related services (2018: £121,000, all of which related to audit and audit-related services).

Table:
2019
2018
£000
£000
Fees payable to the Company’s auditor and its associates for:
The audit of the Company’s annual financial statements
559
382
The audit of the Company’s subsidiaries
533
441
Fees related to the audit of the Company and its subsidiaries
1,092
823
Audit-related assurance services1
64
51
Total fees for audit and audit-related services
1,156
874
Other non-audit assurance services2
534
230
Total fees
1,690
1,104

Questions:
question: What is the total fees in 2019?
answer: 1,690
scale: thousand
question: What is the percentage change in the total fees from 2018 to 2019?
answer: 53.08
derivation: (1,690-1,104)/1,104
scale: percent
question: What is the percentage change in the audit-related assurance services from 2018 to 2019?
answer: 25.49
derivation: (64-51)/51
scale: percent
question: What is the percentage of other non-audit assurance services in total fees in 2019?
answer: 31.6
derivation: 534/1,690
scale: percent
text: GreenSky, Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
(United States Dollars in thousands, except per share data, unless otherwise stated)
text: Note 4. Loan Receivables Held for Sale
text: The following table summarizes the activity in the balance of loan receivables held for sale, net at lower of cost or fair value during the periods indicated.
text: (1) Includes accrued interest and fees, recoveries of previously charged-off loan receivables held for sale, as well as proceeds from transferring our rights to Charged-Off Receivables attributable to loan receivables held for sale. We retain servicing arrangements on sold loan receivables with the same terms and conditions as loans that are originated by our Bank Partners. Income from loan receivables held for sale activities is recorded within interest income and other gains (losses), net in the Consolidated Statements of Operations. We sold loan receivables held for sale to certain Bank Partners on the following dates during the years ended December 31:
text: (2) We temporarily hold certain loan receivables, which are originated by a Bank Partner, while non-originating Bank Partner eligibility is being determined. Once we determine that a loan receivable meets the investment requirements of an eligible Bank Partner, we transfer the loan receivable to the Bank Partner at cost plus any accrued interest. The reported amount also includes loan receivables that have been placed on non-accrual and non-payment status while we investigate consumer inquiries.
text: (3) We received recovery payments of $50, $57 and $238 during the years ended December 31, 2019, 2018 and 2017, respectively. Recoveries of principal and finance charges and fees on previously written off loan receivables held for sale are recognized on a collected basis as other gains and interest income, respectively, in the Consolidated Statements of Operations. Separately, during the years ended December 31, 2019, 2018, and 2017, write offs and other were reduced by $312, $431, and $406, respectively, related to cash proceeds received from transferring our rights to Charged-Off Receivables attributable to loan receivables held for sale. The cash proceeds received were recorded within other gains (losses), net in the Consolidated Statements of Operations.

Table:
Year Ended December 31,
2019
2018
2017
Beginning balance
$2,876
$73,606
$41,268
Additions
157,928
93,240
134,659
Proceeds from sales and borrower payments(1)
(104,858)
(161,009)
(93,044)
Loss on sale
—
—
(500)
Increase in valuation allowance
(1,289)
(92)
(584)
Transfers(2)
251
22
(5,017)
Write offs and other(3)
(2,982)
(2,891)
(3,176)
Ending balance
$51,926
$2,876
$73,606

Questions:
text: 15. QUARTERLY FINANCIAL INFORMATION (UNAUDITED)
text: During the quarter ended December 31, 2019, we purchased a group annuity contract to transfer the pension benefit obligations and annuity administration for a select group of retirees or their beneficiaries to an annuity provider. As a result of the transfer of the pension liability to the annuity provider and other lump sum payments to participants of the Pension Plans, we recognized a non-cash pension settlement charge of $6.7 million during the quarter ended December 31, 2019.
text: In 2019, we recognized a gain on extinguishment of debt from the partial repurchase of our Senior Notes of $0.3 million, $1.1 million and $3.1 million during the quarters ended June 30, 2019, September 30, 2019, and December 31, 2019, respectively.
text: As part of our integration efforts of FairPoint and continued cost saving initiatives, we incurred severance costs of $8.7 million during the quarter ended December 31, 2019.

Table:
Quarter Ended
2019
March 31,
June 30,
September 30,
December 31,
(In thousands, except per share amounts)
Net revenues
$338,649
$333,532
$333,326
$331,035
Operating income
$16,720
$14,300
$23,542
$26,719
Net income (loss) attributable to common stockholders
$(7,265)
$(7,387)
$257
$(5,988)
Basic and diluted earnings (loss) per share
$(0.11)
$(0.10)
$—
$(0.08)

Questions:
question: What was the increase / (decrease) in the net revenues from March 31, 2019 to December 31 2019?
answer: -7614
derivation: 331,035 - 338,649
scale: thousand
question: What is the average Operating income for each quarter in 2019?
answer: 20320.25
derivation: (16,720 + 14,300 + 23,542 + 26,719) / 4
scale: thousand
question: What was the total percentage increase / (decrease) in the Net income (loss) attributable to common stockholders from March 2019 to December 2019?
answer: -17.58
derivation: -5,988 / -7,265 - 1
scale: percent
text: NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (in thousands, except for share and per share data)
text: NOTE 3 — Accounts Receivable
text: The components of accounts receivable are as follows:

Table:
As of December 31,
2019
2018
Accounts receivable, gross
$78,269
$79,902
Less: Allowance for doubtful accounts
(261)
(384)
Accounts receivable, net
$78,008
$79,518

Questions:
question: What was the percentage change in net accounts receivables between 2018 and 2019?
answer: -1.9
derivation: (78,008-79,518)/79,518
scale: percent
text: NOTE 6—INTANGIBLE ASSETS, NET, AND GOODWILL
text: Intangible assets include patents, domain name and other intangibles purchased from GVR, including customer relationships, technology and a trademark. Certain patents were acquired from STI as a result of an asset contribution and were recorded at their carryover basis. The fair value of the patents remained substantially the same as their carrying value at the exchange date. In addition, we acquired other patents and the domain name www.resonant.com through the normal course of business. Intangibles acquired as part of the purchase of GVR were initially recorded at their fair value. Issued patents are amortized over their approximate useful life of 17 years, or 20 years in the case of new patents, once they are approved by their respective regulatory agency. For the patents acquired from STI, we are amortizing them over the remaining useful life of 1 to 11 years as of December 31, 2019. The domain name is amortized over the approximate useful life of 10 years. The other intangibles acquired from GVR are amortized over their useful life of three to five years.
text: Intangible assets, net, consists of the following as of December 31, 2019 and 2018:
text: (1) Includes the impact of foreign currency translation. The total impact at December 31, 2018 was $1,000 and there was no impact at December 31,
2019.
text: During the year ended December 31, 2019 and 2018, we wrote-off $145,000 and $96,000, respectively, of patents we are no longer pursuing. The write-offs are included in research and development expense. There were no impairments to any other intangibles.

Table:
2019
2018
Cost:
Patents
$1,801,000
$1,507,000
Domain name
22,000
22,000
Client Base (1)
144,000
142,000
Trademark (1)
18,000
17,000
Backlog (1)
13,000
13,000
Technology
77,000
77,000
2,075,000
1,778,000
Less: Accumulated amortization
(499,000)
(404,000)
Intangible assets, net
$ 1,576,000
$ 1,374,000

Questions:
question: What are the components recorded under cost for intangible assets?
answer: Patents
Domain name
Client Base
Trademark
Backlog
Technology
question: Which year was the cost for patents lower?
answer: 2018
derivation: $1,507,000 < $1,801,000  
question: What was the change in total cost?
answer: 297000
derivation: 2,075,000 - 1,778,000 
question: What was the percentage change in net intangible assets?
answer: 14.7
derivation: ($1,576,000 - $ 1,374,000)/$ 1,374,000 
scale: percent
text: Outlook and Overview Our operating requirements have historically been funded from cash flows generated from our business and borrowings under our credit facilities.
text: We expect that our future operating requirements will continue to be funded from cash flows from operating activities, existing cash and cash equivalents, and, if needed, from borrowings under our revolving credit facility and our ability to obtain future external financing.
text: We anticipate that we will continue to use a substantial portion of our cash flow to fund capital expenditures, meet scheduled payments of long-term debt, and to invest in future business opportunities.
text: The following table summarizes our cash flows:

Table:
Years Ended December 31,
(In thousands)
2019
2018
2017
Cash flows provided by (used in):
Operating activities
$ 339,096
$ 357,321
$ 210,027
Investing activities
(217,819)
(221,459)
(1,042,711)
Financing activities
(118,481)
(141,920)
821,264
Increase (decrease) in cash and cash equivalents
$ 2,796
$ (6,058)
$ (11,420)

Questions:
question: What was the cash flow from operating activities in 2019?
answer: $ 339,096
scale: thousand
question: What was the cash flow provided by investing activities in 2019?
answer: (217,819)
scale: thousand
question: What was the increase / (decrease) in the cash flow from operating activities from 2018 to 2019?
answer: -18225
derivation: 339,096 - 357,321
scale: thousand
question: What was the average cash flow from investing activities for 2017-2019?
answer: -493996.33
derivation: -(217,819 + 221,459 + 1,042,711) / 3
scale: thousand
question: What was the percentage increase / (decrease) in the Increase (decrease) in cash and cash equivalents from 2018 to 2019?
answer: -146.15
derivation: 2,796 / -6,058 - 1
scale: percent
text: Restricted Shares
text: We granted shares to certain of our Directors, executives and key employees under the 2016 and 2011 Plans, the vesting of which is service-based. The following table summarizes the activity during the twelve months ended March 31, 2019 for restricted shares awarded under the 2016 and 2011 Plans:
text: The weighted-average grant date fair value of the restricted shares is determined based upon the closing price of our common shares on the grant date. During fiscal 2019, a total of 197,917 shares, net of 47,146 shares withheld from the vested restricted shares to cover the employee's minimum applicable income taxes, were issued from treasury. The shares withheld were returned to treasury shares.

Table:
Number of Shares
Weighted-Average Grant-Date Fair Value
(per share)
Outstanding at April 1, 2018
243,354
$10.78
Granted
265,452
14.66
Vested
(197,917)
12.74
Forfeited
(73,743)
11.3
Outstanding at March 31, 2019
237,146
$13.46

Questions:
question: What were the number of outstanding shares at April 1, 2018?
answer: 243,354
question: What was the weighted average granted date fair value per share at April 1, 2018?
answer: $10.78
question: What was the difference between the granted shares and outstanding shares as at April 1, 2018?
answer: 22098
derivation: 265,452 - 243,354
question: What is the total  Weighted-Average Grant-Date Fair Value for Outstanding at April 1, 2018?
answer: 2623356.12
derivation:  243,354* 10.78
question: What was the difference between the vested and granted Weighted-Average Grant-Date Fair Value?
answer: 1.92
derivation: 14.66-12.74
text: Item 6. Selected Financial Data
text: The following selected consolidated financial data set forth below was derived from our historical audited consolidated financial statements and should be read in conjunction with Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations and Item 8 – Financial Statements and Supplementary Data, and other financial data included elsewhere in this Annual Report on Form 10-K. Our historical results of operations are not indicative of our future results of operations.
text: (2) Fiscal 2018 and 2017 have been adjusted for our retrospective adoption of the new accounting standard Revenue from Contracts with Customers (ASC 606). Refer to Note 7 – Revenue of the Notes to Consolidated Financial Statements for details.

Table:
April 26, 2019
April 27, 2018 (2)
April 28, 2017 (2)
April 29, 2016
April 24, 2015
(In millions)
Cash, cash equivalents and short-term investments
$ 3,899
$ 5,391
$ 4,921
$ 5,303
$ 5,326
Working capital
$ 1,743
$ 3,421
$ 2,178
$ 2,786
$ 4,064
Total assets
$ 8,741
$ 9,991
$ 9,562
$ 10,037
$ 9,401
Total debt
$ 1,793
$ 1,926
$ 1,993
$ 2,339
$ 1,487
Total deferred revenue and financed unearned services revenue
$ 3,668
$ 3,363
$ 3,213
$ 3,385
$ 3,197
Total stockholders' equity
$ 1,090
$ 2,276
$ 2,949
$ 2,881
$ 3,414

Questions:
question: What was the working capital in 2019?
answer: 1,743
scale: million
question: What years does the table provide information for total assets?
answer: 2019
2018
2017
2016
2015
question: What was the total debt in 2015?
answer: 1,487
scale: million
question: What was the change in working capital between 2015 and 2016?
answer: -1278
derivation: 2,786-4,064
scale: million
question: How many years did total assets exceed $10,000 million?
answer: 1
derivation: 2016
question: What was the percentage change in Total stockholders' equity between 2018 and 2019?
answer: -52.11
derivation: (1,090-2,276)/2,276
scale: percent
text: Equity Compensation Plan Information
text: The following table summarizes share and exercise price information for our equity compensation plans as of December 31, 2019.
text: (1) Includes 105,000 shares of our common stock issuable upon exercise of outstanding stock options and 340,000 shares issuable upon vesting of outstanding restricted stock units.
text: (2) Represents an individual option grant to our Chairman and Chief Executive Officer outside of, and prior to the establishment of, the 2013 Stock Incentive Plan in October 2013 referred to in the above table. The option agreement pertaining to such option grant contain customary anti-dilution provisions.
text: (3) Does not take into account outstanding restricted stock units as these awards have no exercise price.
text: Our 2013 Stock Incentive Plan (“2013 Plan”) provides for the grant of any or all of the following types of awards: (a) stock options, (b) restricted stock, (c) deferred stock, (d) stock appreciation rights, and (e) other stock-based awards including restricted stock units. Awards under the 2013 Plan may be granted singly, in combination, or in tandem. Subject to standard anti-dilution adjustments as provided in the 2013 Plan, the 2013 Plan provides for an aggregate of 2,600,000 shares of our common stock to be available for distribution pursuant to the 2013 Plan. The Compensation Committee (or the Board of Directors) will generally have the authority to administer the 2013 Plan, determine participants who will be granted awards under the 2013 Plan, the size and types of awards, the terms and conditions of awards and the form and content of the award agreements representing awards. Awards under the 2013 Plan may be granted to our employees, directors and consultants. As of December 31, 2019, there were options to purchase an aggregate of 605,000 shares of common stock outstanding and 340,000 shares issuable upon vesting of outstanding restricted stock units granted under the 2013 Plan, and a balance of 1,780,505 shares of common stock are reserved for issuance under the 2013 Plan.

Table:
Number of securities to be issued upon exercise of outstanding options and rights
Weighted-average exercise price of outstanding options and rights
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column(a))
(a)
(b)
(c)
Equity compensation plans approved by security holders
445,000(1)
$2.34(3)
1,780,505
Equity compensation plans not approved by security holders
500,000(2)
$1.19
—
Total
945,000
$1.39(3)
1,780,505

Questions:
question: What is the proportion of equity compensation plans approved by security holders to the total number of securities to be issued upon exercise of outstanding options and rights?
answer: 0.47
derivation: 445,000/945,000
text: Indefinite-lived Intangible Assets
text: Indefinite-lived intangible assets consist entirely of acquired in-process research and development technology, or IPR&D. The following table sets forth the Company’s activities related to the indefinite-lived intangible assets:
text: The Company performs its annual assessment of indefinite-lived intangible assets on October 31 each year or more frequently if events or changes in circumstances indicate that the asset might be impaired utilizing a qualitative test as a precursor to the quantitative test comparing the fair value of the assets with their carrying amount. Based on the qualitative test, if it is more likely than not that indicators of impairment exists, the Company proceeds to perform a quantitative analysis. Based on the Company’s assessment as of October 31, 2019, no indicators of impairment were identified.
text: In the years ended December 31, 2019 and 2018, no IPR&D impairment losses were recorded. In the year ended December 31, 2017, the Company recognized impairment losses of $2.0 million related to the Company's abandonment of a single IPR&D project.

Table:
Years Ended December 31,
2019
2018
(in thousands)
Beginning balance
$4,400
$4,400
Transfers to developed technology from IPR&D
(4,400)
—
Ending balance
$—
$4,400

Questions:
question: What were the Transfers to developed technology from IPR&D in 2019 and 2018 respectively?
answer: (4,400)
0
scale: thousand
question: What was the change in the Transfers to developed technology from IPR&D from 2018 to 2019?
answer: -4400
derivation: -4,400 - 0
scale: thousand
question: What is the average ending balance for 2018 and 2019?
answer: 2200
derivation: (0 + 4,400) / 2
scale: thousand
question: In which year was Transfers to developed technology from IPR&D negative?
answer: 2019
derivation: locate and analyze Transfers to developed technology from IPR&D in row 5